logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Intervenn Biosciences Raises $201 Million For Ai-Driven Glycoproteomic Platform, Liquid-Biopsy Development

Aug 02, 2021•over 4 years ago

Amount Raised

$201 Million

San Francisco

Description

InterVenn Biosciences today announced the completion of a $201 million Series C financing.

Company Information

Company

Inter Venn Biosciences

Location

San Francisco, California, United States

About

InterVenn Biosciences utilizes a proprietary glycoproteomics biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. For more information about InterVenn Biosciences, please visit the company’s website.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech